Government programs, especially Medicare, are stuck in the past and are not designed to accommodate advancements in modern technology, said Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family Community, and Opportunity at The Heritage Foundation.
Government programs, especially Medicare, are stuck in the past and are not designed to accommodate advancements in modern technology, said Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family Community, and Opportunity at The Heritage Foundation.
Transcript
What is the problem Medicare faces with having Parts A, B, and D? How and why should they be combined?
If you look at Medicare—Medicare is an example that I point to at every government program either here or abroad—the design to the program in healthcare reflects the way the world looked when the program was created. The British National Health Center reflects 1940s medicine and the Medicare program in this country reflects a 1960s picture of medicine and that was very hospital centric. So, it is focused on hospital deductibles and, interestingly enough, the deductible was the cost of a day in the hospital. Nobody bills by days in the hospital anymore that’s no longer done. It’s not like a room rate for a hotel, but that was the way it worked in 1960. They had a flat 20% co-pay for all the physician’s services.
And Medicare didn’t include drugs in 1960 because there weren’t a lot of drugs and they weren’t that expensive. They were mainly some antibiotics and things like that. So, there wasn’t felt to be a need to include drugs. Drugs were like vision care or hearing aids. They were something extra, which Medicare also didn’t cover. So, that is a very 1960s premise. The state of medical technology in the 1960s, I mean this is before drug therapies, before heart transplants, all sorts of things. What happened is that gets frozen in time, because it was written into a government program. So, that’s the problem with designing a government-run program is these things get sort of stuck in a time warp.
The better approach is to focus not on the design of the program, but focus on the people you’re trying to help. And say, "How do we get resources to the people we are trying to help?" If you focus on a government program design then here you are 40 years later trying to update a clearly antiquated structure.
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More